PIN1 and familial pancreatic carcinoma: Thus, targeting Pin1 has emerged as a viable clinical strategy, with one recent study finding that Pin1 inhibition in a pancreatic cancer model disrupted multiple cancer pathways and the immunosuppressive microenvironment, rendering it eradicable by immunochemotherapies [142].